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ABSTRACT 
Atopic dermatitis (AD) is a chronic inflammatory skin disease with a prevalence of 30% for children and 
to 17% for adults. There is observed an increasing trend of occurring AD over time in the world. Many 
factors contribute to the development of the disease, such as environmental, genetic and psychological 
factors. The proper AD treatment should be complexed and consists of skin care with emollients and 
pharmacological treatment. Most of the topical corticosteroids and other drugs have unpleasant side 
effects, therefore, developing new therapies is very useful. To minimalize side effects with a simultaneous 
reduction in the duration, a NPs (nanoparticles) therapy application is highly proposed. On the other 
hand, hydrogels and their shielding properties with high hydrating level and drug delivery capability are 
also widely studied. Some works report on the combination of these two solutions with promising results. 
Material engineering for biomedical applications is a dynamically growing field which offers new drug de-
livery systems (DDS). In this paper, based on the literature we discuss the new methods of AD treatment 
using hydrogels and nanotechnology. 
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Introduction 
Atopic dermatitis (AD) is a common chronic inflam-
matory skin disease initiated by the abnormal immune 
response, microbiome, genetic and/or environmental 
factors [1]. This disease mainly appears in childhood 
but it can also starts in later life [2]. Although prevalence 
in Poland not exceeding 4% [3], studies suggest that 
in the world there is an increasing trend of occurring 
AD over time, especially in children at the age between 
6 and 7 or between 13 and 14, depends on the country 
[4]. Among all cases in the world, the rate for children 
is 30% and 17% for adults [2].
Pathophysiology
AD is characterized by dry skin, erythema, ec-
zematous inflammation and persistent pruritus which 
together have a negative impact on the quality of life 
[2]. Pathogenesis of AD is heterogeneous because both 
genetic and environmental factors are involved in the 
development of the disease [4]. 
Filaggrin (FLG) is an epidermal protein that provides 
the integrity of the skin barrier and promotes corneocytes 
formation. As a result of the physiological intracellular 
transformations of the filaggrin, its metabolites (urocanic 
acid and pyrrolidone-5-carboxylic acid) form compo-
nents of the natural moisturizing factor [5]. FLG loss of 
function variants is the most common genetic mutations 
associated with AD, which the consequence is the re-
duction or lack the filaggrin protein [6]. Furthermore, the 
single-nucleotide polymorphism (SNP) of the genes for 
IL-4, IL-13 and their receptors play a crucial role in the 
immune dysfunctions and the development of AD [1]. 
IL-4 and IL-13 are pro-inflammatory cytokines mediated 
by T-helper 2 cells (Th2) which contribute to the skin 
barrier integrity changes. Increased levels of IL-4 and 
IL-13 inhibit the expression of epidermal proteins like filag-
grin, involucrin and loricrin and play a role in the regulation 
of epidermal homeostasis. In addition, these cytokines 
increase the chances of infection by the destabilization 
of tight junctions and interfere with intercellular transport. 
Not only Th2 but also Th22 cells secrete pro-inflamma-
tory cytokines, such as IL-22 and INF-g, which affect the 
lichenification (Rodrigues and Torres, 2019).
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On the other hand, many environmental and emo-
tional factors strengthen symptoms of AD. Study shows 
that the low humidity reduces the expression of filag-
grin through unknown mechanism [8]. Also, a positive 
linear association between AD prevalence and mean 
and minimum monthly ultraviolet radiation exhibition 
were investigated [9]. Increased sensitivity to dust, air 
pollution and food allergens are mainly observed in 
adult patients with AD. Exacerbated the symptoms of 
AD are also observed after exposure on fragrance (e.g. 
balsam of Peru), hard water and metals including nickel 
and cobalt [10, 11]. Some emotional experiences such 
as stress or deprivation improve symptoms or even give 
rise to the disease [12]. Jaworek et al. suggest that 
there are relations between comorbidity of the AD and 
depression or anxiety. Moreover, the AD’s symptoms 
of patients who suffer from depression and smoke are 
more persistent, than patients who do not smoke [3, 13]. 
Non-Pharmacological and 
Pharmacological Treatments
Treatment should contribute by proper skin care to 
rehydrate, improve skin barrier and repair. Cosmeceu-
ticals for supporting AD treatment contain emollients 
which fulfil all these functions. Regular use of emollients 
in the first six months of life prevent the occurrence of AD 
in children at high risk of the illness [14]. Corticosteroids 
have anti-inflammatory effects but the treatment should 
last no longer than two weeks because of strong side 
effects of the therapy [15]. During systemic therapy 
the most oral used corticosteroid is prednisolone but 
the therapy of AD also consists of immunosuppressant 
treatments include azathioprine, cyclosporine, myco-
phenolate mofetil, methotrexate and dupilumab [16, 17]. 
The last mentioned is a human monoclonal antibody 
which inhibits IL-4 and IL-13. Because of low toxicity 
profile dupilumab is recommended for patients who 
cannot use any other therapy [18]. However, therapy 
needs to be supplemented by vitamins D and E and 
some patients need psychotherapy to relieve symptoms 
of AD [15, 18]. 
Phototherapy is an additional anti-inflammatory 
treatment allowed only for patients without any medical 
contraindications, such as hypertension, heart disease 
and diabetes [19]. This therapy is also a challenge 
for children treatment because of the inconvenience 
associated with the eyewear [20]. The ultraviolet ra-
diations used in phototherapy are ultraviolet A (UVA) 
and ultraviolet B (UVB) which modulate some immune 
pathways, mainly for Th2, Th22 and Th1 cells and cy-
tokines secreted by these cells. The disadvantage of 
this method is the acceleration of skin ageing and skin 
cancer [19, 20]. Narrow-band UVB also significantly 
reduces the infection caused mainly by Staphylococcus 
aureus [21]. Unfortunately, recurrent skin infections are 
very common among patients with AD. The occurrence 
of S. aureus is the most prevalent infection co-occurring 
with AD. Infections are caused by the reduction of the 
skin barrier and bacterial virulence factors secreted by 
S. aureus [22]. Also, there was investigated that the 
S. aureus colonization may be one of the irritating fac-
tors and causes a persistent itching [23]. Sometimes, 
antibiotic therapy is required [24].
Nanotechnology
Term „nanotechnology” is a name of technique 
and method of synthesis materials and particles in 
nano-scale [25]. It was presented for the first time in 
1959 by Richard P. Feynman in his lecture „There’s 
Plenty of Room at the Bottom”. Nanoparticles (NPs) 
are materials with dimension from 1 to 100 nm [24]. De-
pending on the size, chemical and physical character-
istics, NPs are divided into several categories [26]. The 
classifications of NPs has been presented in Table 1.
The biggest advantage of NPs using for medical 
applications is the reduction of the side effects of 
treatment due to the targeting delivery of the drug. 
Two types of DDSs (drug delivery system) can be 
distinguished: active and passive targeting. Passive 
targeting uses the mechanism of enhanced permea-
bility and retention, where NPs penetrate blood vessels 
and accumulate in diseased cells. Active targeting 
involves chemical modifications of NPs’ surface e.g. by 
specific ligand for tumor cells which may provide more 
accurate diagnosis and/or delivery of the substance. 
Both mechanisms allow to introduce less drug to the 
organism and reduce the side effects of therapy [32]. 
Also, it is possible to encapsulate low solubility drugs or 
even two drugs for multidrug therapy or bypass limited 
skin permeability [24]. 
Nanotechnology for AD treatment 
Most solutions using NPs for AD treatment were 
prepared for topical use. Lipid NPs such as liposomes 
show high capability with skin components and also 
polymeric NPs made from polylactic-co-glycolic acid 
(PLGA), polylactic acid (PLA) and chitosan. It shows 
promising results because of biocompatibility, biode-
gradability and non-toxic properties [24, 33]. 
Hydrocortisone and hydroxytyrosol loaded chi-
tosan nanoparticles obtained by ionic gelation method 
formulated as a topical cream showed no toxicity, no 
local-irritation and high tolerance even during 28 days 
of in vivo treatment. Hydrocortisone and hydroxytyrosol 
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Table 1. Classification of NPs including dimensionality and materials
Classification including dimensionality
Dimensionality (D) Examples References
0D quantum dots, solar cells, single-electron transistors, lasers [27]
1D nanowires, nanorods, nanotubes, nanobelts, nanoribbons
2D nanoplates, nanosheets, nanowalls, nanodisks
3D nanoballs, nanocoils, nanopillars, nanoflowers
Classification including material
Inorganic Material Examples References 
Metal nanorods, spherical NPs, 0D hollow nanoporous NPs, [26, 31]
Ceramic nanoshells, nano-scaffold [30]
Organic Carbon-based NPs fullerenes, carbon nanotubes [26]
Polymeric microspheres, micelles [28]
Lipid-based micelles, reverse micelles, liposomes [29]
are glucocorticoids, while chitosan is a natural anti-mi-
crobial and anti-oxidant compound with wound-healing 
properties. It is approved by FDA (Food Drug Admin-
istration) due to its biocompatibility, biodegradability 
and low toxicity [33]. 
To improve the penetration ability of tacrolimus, Zhuo 
et al. [34] encapsulated it into polymeric NPs and coated it 
all with hyaluronic acid. NPs were obtained by high-pres-
sure homogenization–solvent evaporation method. 
In result, they received controlled released drug system. 
Coat made of hyaluronic acid may provide limited water 
diffusion into polymeric NPs and in effect slows rapid 
drug release to 8 hours. Obtained in vivo test on AD mice 
group and control group have shown greater control over 
AD-like skin lesions. Moreover, the histological examina-
tion has shown less infiltration of inflammatory cells and 
increasing skin integrity in the treated group. 
Chitosan-NPs coated with hyaluronic acid have 
been also proposed to delivery betamethasone val-
erate. NPs were prepared by high-pressure homoge-
nization–evaporation method and obtained spherical 
shape particles with smooth surfaces. The optimal drug 
release was obtained in pH = 5.5 what mimics the mi-
croenvironment of the inflammation process during AD. 
Moreover, NPs with betamethasone valerate efficiently 
retained into the epidermis and the dermis [35]. 
To improve solubility and anti-pollutant activity of 
7,3',4' — Trihydroxyisoflavone (734THI), Huang et al. 
prepared polyvinylpyrrolidone (PVP) NPs loaded with 
potential drug — 734THI [36]. This substance shows 
antioxidant, skin whitening and anti-AD properties that 
have a promising application in dermatology and cos-
metology. NPs did not show HaCaT cell line cytotoxicity. 
Moreover, 734THI loaded into NPs has higher anti-in-
flammatory activity, compared with raw substance. 
Another tacrolimus-loaded thermosensitive solid 
lipid NPs were obtained by a solvent emulsification-dif-
fusion technique. The shell of the particles was coated 
by different types of surfactants. It was confirmed that 
the drug release depends on the melting point of the 
surfactant. In addition, this NPs are able to penetrate 
a deeper layer of the skin and release the drug at 
37oC [37]. 
NPs for veterinary application were prepared 
by two-step desolvation method. Cytosine-phos-
phate-guanine oligodeoxynucleotides were encapsu-
lated into gelatin NPs as a immunomodulatory factor 
which increases secretion of IL-10 and decreases 
IL-4 level in atopic dogs. This study, as the only one 
in this paper, assumes subcutaneous injections of the 
potential drug [38]. 
Despite the side effects of silver NPs, their potential 
use in dermatology is still being tested. Kang et al. 
compared the immune response of mast cells to the 
use of 5 nm and 100 nm silver NPs. Results suggest that 
5 nm silver NPs indicate mast cells degranulation and 
generate oxidative stress via an increase level of Ca2. 
Moreover, histological examination of mice skin treated 
5 nm silver NPs have shown an increased number of 
mast cells. Strong immune response was not observed 
for 100 nm silver NPs [39].
Levocetirizine is an antihistaminic drug and 
H1 blocker used in the treatment of chronic idiopathic 
urticaria, hay fever and seasonal allergic rhinitis. It was 
shown that levocetirizine is able to reduce IL-13 and 
IL-4 level and increase IL-10 level which has a promising 
potential treatment for AD. Another novel proposition are 
flexible vesicles loaded with levocetirizine for topical use 
characterized by no pathological changes in histological 
studies and ability to penetrate the skin barrier [40]. 
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Hydrogels 
In general, hydrogels are three-dimensional 
polymeric matrices with hydrophilic and adsorption 
properties but without possibilities to dissolving. The 
classification is complexed and depends on the ori-
gin, properties, nature of polymeric side groups and 
response to the stimuli [41]. Hydrogels were fully de-
fined for the first time by Wichterle and Lim in 1960. The 
definition included biocompatibility and high water 
affinity [42]. After that time, hydrogels were intensively 
studied and the process of developing the hydrogels 
formulations was divided into three stages. Nowadays 
hydrogels being designed as supramolecular compo-
sitions with excellent biocompatibility, ability to respond 
to specific stimuli (pH, temperature) and elicit specific 
response [41]. 
Hydrogels for AD treatment
Hydrogels are attractive vehicles for the transdermal 
drug delivery but the biggest limitation is the ability to 
delivery only hydrophobic drugs. Many studies use 
compositions of micelles and hydrogels to obtain DDS 
(drug delivery system) complex despite the hydropho-
bic or hydrophilic drug nature [41].
Alginate hydrogels with cynaroside as an anti-in-
flammatory and anti-allergic natural substance were 
tested as a potential DDS for AD. The results show 
a reduction in the number of T cells in histological exam-
ination. Moreover, alginate hydrogels with cynaroside 
are characterized by high bioadhesion and viscosity 
properties [43]. 
 Another proposition with natural drug substance 
is hydrogel with Rhus verniciflua extract (RVE). RVE is 
widely known by its anti-microbial, anti-inflammatory, 
anti-allergic and AD-protective properties. Authors ob-
tained pullulan-RVE film for topical application which 
limits the mast cells migration in AD lesions. Total 
amount of extract was released from this system by 
6 hours, but the effect of pullulan without drug sub-
stance have not been investigated [44]. 
To reduce the pruritus associated with AD, Kircik 
made desonide hydrogel. Desonide is a topical cor-
ticosteroid used for various skin conditions. Hydrogel 
treatment for 3–7 days significantly improved skin 
condition and potentially quality of patients’ life [45].
Thermosensitive transdermal hydrogel made of 
poloxamer is a dual-functional moisturizing and medic-
inal DDS. Liquid formula has been transformed into gel 
almost immediately after the temperature rises to 37oC. 
In vitro cytotoxicity analysis have shown high safety and 
biocompatibility of use [46].
As mentioned earlier, some systems contain NPs 
and hydrogel to ensure penetration of the hydrophilic 
substances. Augustin et al. elaborated a pilot study of 
liposomal polyvinylpyrrolidone-iodine hydrogel. This 
system were well tolerated by most patients even with 
sensitive skin conditions. In addition, it may be a poten-
tial treatment method for a inflammatory skin diseases 
associated with bacterial colonization [47]. 
Utilizing anti-inflammatory potential of prostaglandin 
PGJ2, hydrogel vehicles were made and compared with 
tacrolimus treatment and no treatment rats group. Both, 
tacrolimus and PGJ2 hydrogels reduced the IgE level in 
serum and decreased mast cells infiltration. There were 
no significant differences between PGJ2 and tacrolimus 
groups. These findings suggest that PGJ2 hydrogels 
may be a potential topical treatment for AD [48].
Summary and conclusions 
AD is a serious skin ailment correlated with environ-
mental factors and mental condition. The AD treatment 
is a complexed and long-lasting process causing many 
side effects and bad quality of life. Moreover, most of 
them may not be effective. New DDSs provide multidrug 
cure with simultaneous high moisture level and relieved 
feeling. In addition, novel materials for the medical 
application do not require much duration of treatment 
compared with the traditional medical approach. NPs 
are great vehicles for drugs which require deep skin 
penetration but on the other hand, hydrogels also pro-
vide a high level of hydration and wound healing. The 
examples cited in this paper require further research but 
the in vitro and in vivo results are promising and shed 
new light on pharmacology.
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